Next Article in Journal
Evaluation of Cinnamon Essential Oil and Its Emulsion on Biofilm-Associated Components of Acinetobacter baumannii Clinical Strains
Previous Article in Journal
A VersaTile Approach to Reprogram the Specificity of the R2-Type Tailocin Towards Different Serotypes of Escherichia coli and Klebsiella pneumoniae
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Antibiotic Prescription Practice and Resistance Patterns of Bacterial Isolates from a Neonatal Intensive Care Unit: A Retrospective Study from Jordan

1
Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Yarmouk University, Irbid 21163, Jordan
2
Biopharmaceutics and Clinical Pharmacy Department, Faculty of Pharmacy, AI-Ahliyya Amman University, Amman 11941, Jordan
3
Clinical Pharmacy Department, Al Basheer Government Hospital, Ministry of Health, Amman 11941, Jordan
4
Microbiology Department, Al Basheer Government Hospital, Ministry of Health, Amman 11941, Jordan
5
Pharmacy and Clinical Pharmacy Directorate, Ministry of Health, Amman 11941, Jordan
*
Author to whom correspondence should be addressed.
Antibiotics 2025, 14(1), 105; https://doi.org/10.3390/antibiotics14010105
Submission received: 26 November 2024 / Revised: 7 January 2025 / Accepted: 10 January 2025 / Published: 18 January 2025
(This article belongs to the Section Antibiotic Therapy in Infectious Diseases)

Abstract

:
Background/Objectives: Neonatal sepsis is a systemic inflammation in neonates caused by bacteria, viruses, or fungi that can progress into severe conditions. In developing countries, neonatal sepsis is a major cause of mortality and a major public health issue with a high prevalence. This study aims to evaluate the antibiotic prescription practice and resistance patterns of bacterial isolates from the neonatal intensive care unit (NICU) at the largest governmental hospital in Amman, Jordan. Methods: This was a retrospective cross-sectional study. The antibiotic prescription practice and resistance patterns of bacterial isolates from the NICU at Al Basheer Government Hospital in Amman, Jordan, were evaluated. The hospital’s microbiology lab database and medical records were the sources of the retrospective data collection. Results: A total of 266 neonates treated with antibiotics were assessed. The findings showed that most neonates had late-onset sepsis (LOS) (65.4%). The penicillin group of antibiotics (ampicillin) was the most highly prescribed first empiric antibiotic for LOS and early-onset sepsis (EOS) (61.7%). Aminoglycosides (60.9%) were the most prescribed antibiotics as a second empiric treatment for EOS and LOS. The culture results showed that resistance to antibiotics was as follows: 15.4% of the culture samples were resistant to penicillin (Micrococcus and Viridans streptococci), 13.9% were resistant to cefotaxime (Klebsiella pneumoniae and Viridans streptococci), 13.2% were resistant to cefoxitin (Klebsiella pneumoniae and Staphylococcus epidermidis), and 12.4% were resistant to oxacillin (Klebsiella pneumoniae and Staphylococcus epidermidis). Conclusions: This retrospective study sheds light on the antibiotic prescription practice and resistance patterns of bacterial isolates from newborns with sepsis. The results highlight the high rates of antibiotic resistance. These findings underline the urgent need for improved antibiotic stewardship and infection control strategies to prevent resistance from spreading further.

1. Introduction

Neonatal sepsis is a systemic inflammation in neonates caused by bacteria, viruses, or fungi that can progress into severe conditions [1]. Rudd et al. examined the global burden of sepsis and its incidence patterns from 1990 to 2017. Their study revealed a decrease in sepsis incidence by 37.0% from 1990 to 2017 and a drop in mortality by 52.8% [2]. Sepsis incidence and mortality are inconsistent worldwide and vary considerably among regions [3]. In developing countries, neonatal sepsis is a major cause of mortality and a major public health issue with a prevalence as high as 29.92% [4].
Neonatal sepsis is categorized into two groups depending on the time of onset. Early-onset neonatal sepsis is a confirmed infection in the blood or cerebrospinal fluid within the first 72 h of life, and late-onset if it occurs between 3 and 28 days [5]. Some experts provide a cut-off time of 7 days to define the early and late onset of neonatal sepsis [6,7]. EOS is an infection that occurs before and/or during delivery (from the female genitourinary system), whereas late-onset most probably occurs through the surrounding environment after delivery such as hospitals or caregivers [8,9].
EOS involves several types of bacteria such as Streptococcus agalactiae, Escherichia coli, Staphylococcus aureus, Enterococcus, and Streptococcus pneumonia. However, LOS includes coagulase-negative staphylococci, Klebsiella pneumoniae, and Acinetobacter baumannii [10].
A recent review by Glaser et al. revealed that the most prevalent pathogens in EOS are Group B Streptococcus and Escherichia coli, and coagulase-negative staphylococci for LOS [11].
However, these epidemiological data may differ based on the setting. Dong et al., in a review of neonatal sepsis in China, reported that the prevalence of Group B Streptococcus in EOS differs from that in developed countries [12].
Similarly, Russel et al.’s review showed distinct differences in the etiology between low-, middle-, and high-income countries [13].
Neonatal sepsis is a severe disease with detrimental consequences; therefore, empirical therapy with broad-spectrum antibiotics is necessary for neonates with risk factors and/or suspected sepsis [14]. However, the use of inappropriate broad-spectrum antibiotics and for a longer-than-needed duration in neonatal intensive care units leads to the emergence of multidrug-resistant micro-organisms, which limits the number of effective antibiotics [15]. Antibiotic susceptibility patterns, which guide the antibiotic profile used, differ from one institution to another. Wang et al. reported that most isolated coagulase-negative staphylococci specimens were resistant to β-lactam drugs [16]. Pokhrel et al.’s study showed that coagulase-negative staphylococci were resistant to oxacillin, cefotaxime, and meropenem, but susceptible to vancomycin and linezolid [17]. Tan et al. evaluated antibiotic resistance in neonatal invasive bacterial infections in China from 2012 to 2019. Their study reported that all Staphylococcus aureus specimens were not susceptible to ampicillin and penicillin and half of these cultures were resistant to methicillin. Additionally, all Group B Streptococcus were susceptible to penicillin and ampicillin, but most frequently resistant to erythromycin and clindamycin [18]. Based on previous evidence, medical institutions should assess antibiotic resistance patterns regularly to identify adequate and effective antibiotics.
This study aims to evaluate the antibiotic prescription practice and resistance patterns of bacterial isolates from the neonatal intensive care unit at AlBasheer Hospital, the largest governmental hospital and neonatal intensive care unit, in Amman, Jordan.

2. Methodology

This was a retrospective cross-sectional study. Antibiotic resistance patterns and microbiological features in the NICU at Al Basheer Government Hospital in Amman, Jordan, were evaluated in this study. November 2022 to May 2024 was the study’s period. A reference number (17371/IRB) for the IRB approval was obtained from the Jordanian Ministry of Health.

2.1. Study Sittings

One of the biggest public hospitals in Amman, Jordan, Al Basheer Hospital, handles a sizable number of neonatal patients, making it the perfect location for the study’s assessment of antibiotic resistance in this group. The NICU, which admits newborns in need of acute care owing to a variety of infections, preterm, and other issues, was the specific focus of the study. This NICU usually has approximately 3–4 surgery patients per month. Most patients are ventilated with mechanical ventilation or with a nasal cannula. Moreover, all the neonates with very low or low birth weight (<1.5 kg) in the very preterm category were on total parenteral nutrition (TPN), had intravenous catheters, and were ventilated.

2.2. Study Participants and Data Collection

The hospital’s microbiology lab database and medical records were the sources of the retrospective data collection. The data that was obtained was as follows: Neonate demographic information, including age, gender, gestational age, and birth weight. Clinical information, such as the diagnosis, length of NICU stay, and underlying health issues. Microbiological information, such as the kind of bacteria that were isolated from blood. Patterns of antibiotic susceptibility as established by the hospital’s laboratory. Treatments with antibiotics, classes, and specific agents. The microbiological method used in this hospital was the conventional culture method for microbial isolation. Strict criteria were used to differentiate between true pathogens and contaminants according to the standard operating procedures (SOPs) and Clinical & Laboratory Standards Institute (CLSI) guidelines. The guidelines stress the importance of sterile collection, proper preparation, and adequate blood volume for reliable results. Moreover, the guideline recommends collecting 2, or preferably 3, blood culture sets for each septic episode. A contaminant will usually be present in only one bottle of a set of blood culture bottles, in contrast to a true bloodstream infection, in which multiple blood culture bottles/sets will be positive.

2.3. Statistical Analyses

Statistical software, such as SPSS version 25, was used to evaluate the data once they were entered into a secure database. The microbiological data, antibiotic prescription practice, antibiotic resistance patterns, clinical aspects, and demographics were all summarized using descriptive statistics. Categorical variables were expressed as frequencies and percentages, and continuous variables were provided as means (±standard deviation). A p-value of ≤0.05 was considered statistically significant.

2.4. Ethical Approval

The Jordanian Ministry of Health’s Institutional Review Board (IRB) gave its approval to this study (Reference number: 17371/IRB). Since the study was retrospective, the patients’ or their guardians’ informed consent was unnecessary. To maintain confidentiality, all the data were anonymized, and only the research team had access to them.

3. Results

3.1. Characteristics of the Participants

The prescription practices related to antibiotics and patterns of antibiotic resistance of bacterial isolates obtained from neonates with sepsis were assessed over eighteen months. During this period, 266 neonates who were treated with antibiotics were assessed. The majority (97.0%) of the neonates were admitted for the first time to the hospital. The mean gestational age was 35 days. Only 12% of the neonates were born preterm with very low birth weight. About half of the patients were male (56.8%) and delivered by cesarean section (59.4%). Signs of infection included chest retraction (19.9%), high levels of CRP (19.1%), and tachypnea (13.2%). More than one-third of the neonates were diagnosed with respiratory distress syndrome (RDS). Most neonates had LOS (65.4%). The late onset of sepsis was higher in the male neonates (n = 107), those born preterm (n = 29), and those with low birth weight (n = 26) [p-value = 0.032, 0.003, and 0.031, respectively] compared to the females and those born on term and with normal gestational weight. The mortality rate among the neonates in this study was (1.88%). Characteristics of the neonatal patients are summarized in Table 1.

3.2. Characteristics of Antibiotic Prescription for the Treatment of Neonatal Sepsis

In this study, the range of empiric antibiotics used consecutively was between 0 and 6. About 70% of the neonates were treated with two antibiotics, and only 0.8% were treated with six antibiotics. None of the neonates received antibiotics to treat intra-amniotic infection, while 1.5% percent only of their mothers received prenatal antibiotics. The physician decided to change the antibiotic treatment after the results of the specimen culture in 45.1% of the neonates, where the number of targeted antibiotics ranges between 1 and 4 antibiotics, as seen in Table 2.
The mean number of empirical antibiotics used in LOS was higher than in EOS (2.32 vs. 2.0, p-value 0.013).

3.3. Types of Bacterial Isolates from Neonatal Sepsis Patients in Jordan

The most common types of Gram-positive bacterial isolates were Micrococcus luteus (37.5%), Staphylococcus epidermidis (36.2%), and Streptococcus viridans (6.9%). On the other hand, the most common types of Gram-negative bacterial isolates were Klebsiella pneumonia (41.2%), Acinetobacter baumanni (17.6%), and Escherichia coli (14.7%). For Gram-positive bacteria in late-onset sepsis, the most common cause was Staphylococcus epidermidis (25.9%) followed by Micrococcus luteus (22.8%). The results are shown in Table 3.

3.4. Practice of Antibiotic Prescription for Neonatal Sepsis Patients in Jordan

The penicillin group of antibiotics (ampicillin) was the most highly prescribed first empiric antibiotic for neonates (61.7%), followed by dehydropeptidase/carbapenems such as meropenem (11.3%) and glycopeptides (10.9%). Aminoglycosides (60.9%) were the most prescribed antibiotics as a second empiric treatment. On the other hand, polymixins and nitroimidazole were the least prescribed for the treatment of neonatal infections. The results of antibiotic prescription practices for neonatal sepsis are described in Table 4.
The results of the specimen culture were available for 232 of the participants, and treatment was amended according to the culture results. Vancomycin was prescribed as a replacement for the previous antibiotic (34.2%), followed by aminoglycosides (28.3%). If the physician decided to make another change in the treatment, meropenem was most prescribed (32.5%). Only third-generation cephalosporins and meropenem were an option in all numbers of changed antibiotics, as shown in Table 5.

3.5. Resistance Patterns to Antibiotics Used for Neonatal Sepsis Patients in Jordan

The culture results showed that resistance to antibiotics was as follows: 15.4% of the culture samples were resistant to penicillin (Micrococcus and Viridans streptococci), 13.9% were resistant to cefotaxime (K. pneumonia and Viridans streptococci), 13.2% were resistant to cefoxitin (K. pneumonia and Staph. Epidermis), and 12.4% were resistant to oxacillin (K. pneumonia and Staph. Epidermis). Details are shown in Table 6.

4. Discussion

The results of this study shed light on the antibiotic prescription practice and resistance patterns of bacterial isolates from newborns with sepsis hospitalized in a Jordanian NICU. During the study period, neonates receiving antibiotic treatment for sepsis were assessed, indicating many noteworthy clinical features, prescription patterns, and microbiological resistance patterns.
Regarding the neonates’ demographics, it appears that term infants with a mean gestational age of 35 days made up the majority of the cases. On the other hand, most neonates in the current study had late-onset sepsis, especially those with low birth weight and preterm. This result is consistent with earlier research, which found that low birth weight and preterm delivery were major risk factors for neonatal sepsis because of the immune system’s immaturity and extended NICU stays, which could expose patients to more nosocomial infections [19,20]. The gender disparity, where the male newborns had a higher risk of late-onset sepsis, is also in line with previous research suggesting that immunological or hormonal disparities may make male neonates more susceptible to infections [21].
The study’s antibiotic use patterns show that penicillin, particularly ampicillin, is the most common first-line empiric therapy for neonatal sepsis. This preference may be due to ampicillin’s documented efficiency in targeting the most frequent bacteria in EOS, including Group B Streptococcus and Escherichia coli [22]. The usage of aminoglycosides as a second-line treatment is most likely due to their synergistic effects when taken with other antibiotics, notably in the treatment of Gram-negative infections [23]. According to Hodoșan et al., the combination of ampicillin and gentamicin has been the most effective empirical treatment for sepsis for many years due to its etiological variability [24].
The current study findings show that in about 45% of the cases, the results of the culture were used to modify the empirical antibiotic selection. This is a sign of good clinical practice since it shows that antibiotic resistance may be fought by making adjustments based on microbial sensitivity [25]. Findings, however, indicate that managing sepsis in older neonates is more complex, frequently requiring broader-spectrum antibiotic coverage initially due to increased exposure to nosocomial pathogens. Specifically, LOS was found to be associated with a higher mean number of empiric antibiotics compared to EOS (2.32 vs. 2.0, p = 0.013). These findings are consistent with the reported literature. A recent narrative review about antimicrobial resistance among neonates stated that long-lasting hospitalized neonates are more likely to become infected with multidrug-resistant micro-organisms [26].
According to the microbiological reports in this study, Klebsiella pneumoniae, Acinetobacter baumannii, and Escherichia coli dominated the Gram-negative isolates, whereas Micrococcus luteus and Staphylococcus epidermidis were the most common Gram-positive isolates. Given that Acinetobacter baumannii and Klebsiella pneumoniae are known to be multidrug-resistant and frequently linked to infections acquired in hospitals [27,28], the high incidence of these bacteria is especially worrying. In addition to being a common contaminant, the presence of coagulase-negative staphylococci like Staphylococcus epidermidis may also point to an over-reliance on invasive medical equipment like central venous catheters in this population, which increases the risk of bloodstream infections [29].
The test results for antibiotic susceptibility showed a concerning trend of resistance caused by Micrococcus, Viridans streptococci, Klebsiella pneumoniae, and Staphylococcus epidermidis. Resistance rates to commonly used antibiotics—penicillin, cefotaxime, cefoxitin, and oxacillin—were found to be substantial, ranging from 12.4% to 15.4%. These findings align with the worldwide rising antimicrobial resistance (AMR) patterns among different bacterial species [30]. This shows that resistant bacteria in the NICU may have emerged as a result of the overuse or improper usage of these antibiotics [31]. According to a systematic literature review, the findings highlight the fact that the vast majority of infections exhibit strong resistance to widely used antibiotics [32].
According to a recent systematic review, 28 studies revealed that E. coli showed high levels of resistance to ampicillin, cephradine, penicillin, and amoxicillin. Thirteen studies revealed that Klebsiella spp. had significant resistance to second- and third-generation antibiotics, such as cefaclor and cefotaxime. Fifteen studies indicated high resistance to nearly all the tested antibiotics in Acinetobacter spp. [33]. The necessity for careful stewardship in antibiotic prescribing methods to prevent the development of further resistance is highlighted by the comparatively high resistance to gentamicin and trimethoprim/sulphamethoxazole [34]. A recent review about early-onset neonatal sepsis in low- and middle-income countries concluded that over the past ten years, there has been an alarming rise in antimicrobial resistance [35]. As multidrug-resistant organisms can complicate treatment and increase infant mortality, the study’s results highlight the importance of the ongoing observation of antibiotic resistance patterns in NICUs [36]. While important in life-threatening cases such as sepsis, the relatively high incidence of empiric antibiotic treatment prior to culture results should be counterbalanced with timely de-escalation based on susceptibility profiles to minimize the risk of resistance development [37].
A number of actions could be suggested in order to counteract the growing trend of antibiotic resistance: Improved Antibiotic Stewardship Programs: It is imperative to put strong restrictions on the use of antibiotics into place, particularly when it comes to the empirical use of broad-spectrum antibiotics [38,39,40]. Regular audits and feedback on prescribing procedures could help achieve this [39]. Targeted Therapy: By using fast diagnostic tests more frequently, antibiotic therapy can be more quickly tailored, avoiding needless exposure to a wide range of antibiotics [41,42,43]. Moreover, to combat the growing threat of resistance in NICU populations, research into novel antimicrobials and alternative treatments is necessary, especially in light of the growing resistance to important antibiotics like vancomycin [44].
The study’s retrospective methodology has drawbacks because it may result in biases and missing data. The results may not have been as applicable to other NICUs in Jordan or throughout the world because the investigation was restricted to infants admitted to a single hospital. This approach offers a well-defined plan for assessing antibiotic resistance patterns and prescription practice in a susceptible newborn population, highlighting the necessity of longer-term surveillance to obtain more thorough data on antibiotic resistance patterns.

5. Conclusions

This retrospective study sheds light on the antibiotic prescription practice and resistance patterns of bacterial isolates from newborns with sepsis in a Jordanian NICU. The results highlight high rates of antibiotic resistance. These findings underline the urgent need for improved antibiotic stewardship and infection control strategies to prevent resistance from spreading further. Despite being therapeutically justifiable, the intense reliance on empirical antibiotic treatment may be a contributing factor to the escalating issue of AMR.
The use of intrapartum antibiotic prophylaxis for high-risk deliveries (such as those with prolonged labor or the preterm rupture of membranes) should be encouraged in Jordan. In addition, we should increase pregnant women’s knowledge of the value of prenatal care, delivery planning, and receiving medical help as soon as possible. Knowing the risks of sepsis and other pregnancy-related issues can help perform vaginal swab screening, encourage early hospital visits, and decrease the need for emergency hospitalizations in regions with limited access to health care. Moreover, poor countries like Jordan may obtain funds and resources for improving newborn care by working with international health organizations like the United Nations Children’s Fund (UNICEF) and the World Health Organization (WHO).

Author Contributions

Conceptualization, M.A. (Mariam Alameri) and L.G.; methodology, M.A. (Mariam Alameri), L.G. and H.S.; software, M.A. (Mariam Alameri) and M.A. (Mervat Alsous); validation, M.A. (Mariam Alameri), M.A. (Mervat Alsous) and L.G.; formal analysis, M.A. (Mariam Alameri) and M.A. (Mervat Alsous); investigation, M.A. (Mariam Alameri), L.G., M.A. (Mervat Alsous), A.Y. and H.S.; resources, M.A. (Mariam Alameri), L.G., M.A. (Mervat Alsous), A.Y., A.T., S.S. and H.S.; data curation, M.A. (Mariam Alameri), L.G., M.A. (Mervat Alsous), A.Y., A.T., S.S. and H.S.; writing—original draft preparation, M.A. (Mariam Alameri), L.G., M.A. (Mervat Alsous), A.Y., A.T., S.S. and H.S.; writing—review and editing, M.A. (Mariam Alameri), L.G., M.A. (Mervat Alsous), A.Y., A.T., S.S. and H.S.; visualization, M.A. (Mariam Alameri), L.G., M.A. (Mervat Alsous), A.Y., A.T., S.S. and H.S.; supervision, M.A. (Mariam Alameri) and L.G.; project administration, M.A. (Mariam Alameri), L.G., M.A. (Mervat Alsous), A.Y., A.T., S.S. and H.S.; funding acquisition, not available. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board (IRB) of The Jordanian Ministry of Health (protocol code 17371/IRB, 16 October 2022).

Informed Consent Statement

Patient consent was waived due to the study’s nature, which was retrospective; the patients’ or their guardians’ informed consent was not necessary. All the data were anonymized to maintain confidentiality, and only the research team had access to them.

Data Availability Statement

The data underlying this article will be shared upon reasonable request to the corresponding author.

Acknowledgments

The authors would like to acknowledge all the staff at Al Basheer Government Hospital in Amman, Jordan.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Goldstein, B.; Giroir, B.; Randolph, A. International pediatric sepsis consensus conference: Definitions for sepsis and organ dysfunction in pediatrics. Pediatr. Crit. Care Med. 2005, 6, 2–8. [Google Scholar] [CrossRef] [PubMed]
  2. Rudd, K.E.; Johnson, S.C.; Agesa, K.M.; Shackelford, K.A.; Tsoi, D.; Kievlan, D.R.; Colombara, D.V.; Ikuta, K.S.; Kissoon, N.; Finfer, S.; et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: Analysis for the Global Burden of Disease Study. Lancet 2020, 395, 200–211. [Google Scholar] [CrossRef] [PubMed]
  3. Seale, A.C.; Blencowe, H.; Manu, A.A.; Nair, H.; Bahl, R.; Qazi, S.A.; Zaidi, A.K.; Berkley, J.A.; Cousens, S.N.; Lawn, J.E. Estimates of possible severe bacterial infection in neonates in sub-Saharan Africa, south Asia, and Latin America for 2012: A systematic review and meta-analysis. Lancet Infect. Dis. 2014, 14, 731–741. [Google Scholar] [CrossRef] [PubMed]
  4. Amare, D.; Mela, M.; Dessie, G. Unfinished agenda of the neonates in developing countries: Magnitude of neonatal sepsis: Systematic review and meta-analysis. Heliyon 2019, 5, e02519. [Google Scholar] [CrossRef] [PubMed]
  5. Zakariya, B.P.; Bhat, V.; Harish, B.N.; Arun Babu, T.; Joseph, N.M. Neonatal sepsis in a tertiary care hospital in South India: Bacteriological profile and antibiotic sensitivity pattern. Indian J. Pediatr. 2011, 78, 413–417. [Google Scholar] [CrossRef] [PubMed]
  6. Wynn, J.L. Defining neonatal sepsis. Curr. Opin. Pediatr. 2016, 28, 135–140. [Google Scholar] [CrossRef] [PubMed]
  7. Cizmeci, M.N.; Kara, S.; Kanburoglu, M.K.; Simavli, S.; Duvan, C.I.; Tatli, M.M. Detection of cord blood hepcidin levels as a biomarker for early-onset neonatal sepsis. Med. Hypotheses 2014, 82, 310–312. [Google Scholar] [CrossRef]
  8. Schuchat, A. Neonatal group B streptococcal disease--screening and prevention. N. Engl. J. Med. 2000, 343, 209–210. [Google Scholar] [CrossRef]
  9. Stoll, B.J.; Hansen, N.; Fanaroff, A.A.; Wright, L.L.; Carlo, W.A.; Ehrenkranz, R.A.; Lemons, J.A.; Donovan, E.F.; Stark, A.R.; Tyson, J.E.; et al. Changes in pathogens causing early-onset sepsis in very-low-birth-weight infants. N. Engl. J. Med. 2002, 347, 240–247. [Google Scholar] [CrossRef] [PubMed]
  10. Attia Hussein Mahmoud, H.; Parekh, R.; Dhandibhotla, S.; Sai, T.; Pradhan, A.; Alugula, S.; Cevallos-Cueva, M.; Hayes, B.K.; Athanti, S.; Abdin, Z.K.B. Insight into Neonatal Sepsis: An Overview. Cureus 2023, 15, e45530. [Google Scholar] [CrossRef]
  11. Glaser, M.A.; Hughes, L.M.; Jnah, A.; Newberry, D. Neonatal Sepsis: A Review of Pathophysiology and Current Management Strategies. Adv. Neonatal Care 2021, 21, 49–60. [Google Scholar] [CrossRef] [PubMed]
  12. Dong, Y.; Basmaci, R.; Titomanlio, L.; Sun, B.; Mercier, J.C. Neonatal sepsis: Within and beyond China. Chin. Med. J. (Engl.) 2020, 133, 2219–2228. [Google Scholar] [CrossRef]
  13. Russell, N.; Barday, M.; Okomo, U.; Dramowski, A.; Sharland, M.; Bekker, A. Early-versus late-onset sepsis in neonates—Time to shift the paradigm? Clin. Microbiol. Infect. 2024, 30, 38–43. [Google Scholar] [CrossRef] [PubMed]
  14. Zea-Vera, A.; Ochoa, T.J. Challenges in the diagnosis and management of neonatal sepsis. J. Trop. Pediatr. 2015, 61, 1–13. [Google Scholar] [CrossRef] [PubMed]
  15. Dong, Y.; Speer, C.P. Late-onset neonatal sepsis: Recent developments. Arch. Dis. Child Fetal Neonatal Ed. 2015, 100, F257–F263. [Google Scholar] [CrossRef] [PubMed]
  16. Wang, J.; Zhang, H.; Yan, J.; Zhang, T. Literature review on the distribution characteristics and antimicrobial resistance of bacterial pathogens in neonatal sepsis. J. Matern. Fetal Neonatal Med. 2022, 35, 861–870. [Google Scholar] [CrossRef] [PubMed]
  17. Pokhrel, B.; Koirala, T.; Shah, G.; Joshi, S.; Baral, P. Bacteriological profile and antibiotic susceptibility of neonatal sepsis in neonatal intensive care unit of a tertiary hospital in Nepal. BMC Pediatr. 2018, 18, 208. [Google Scholar] [CrossRef]
  18. Tan, J.; Wang, Y.; Gong, X.; Li, J.; Zhong, W.; Shan, L.; Lei, X.; Zhang, Q.; Zhou, Q.; Zhao, Y.; et al. Antibiotic resistance in neonates in China 2012–2019: A multicenter study. J. Microbiol. Immunol. Infect. 2022, 55, 454–462. [Google Scholar] [CrossRef] [PubMed]
  19. Köstlin-Gille, N.; Härtel, C.; Haug, C.; Göpel, W.; Zemlin, M.; Müller, A.; Poets, C.F.; Herting, E.; Gille, C. Epidemiology of early and late onset neonatal sepsis in very low birthweight infants: Data from the German Neonatal Network. Pediatr. Infect. Dis. J. 2021, 40, 255–259. [Google Scholar] [CrossRef]
  20. Nyenga, A.M.; Mukuku, O.; Wembonyama, S.O. Neonatal sepsis: A review of the literature. Theory Clin. Pract. Pediatr. 2021, 3, 94–101. [Google Scholar] [CrossRef]
  21. Ramiro-Cortijo, D.; Zozaya-Nieto, C.; López de Pablo, A.L.; López-Giménez, M.R.; Saenz de Pipaon, M.; Arribas, S.M. Higher risk of late-onset sepsis in very low birth weight male preterm infants. Rev. Med. Univ. 2018, 20, 118–124. [Google Scholar] [CrossRef]
  22. Polin, R.A.; the Committee on Fetus and Newborn; Papile, L.-A.; Baley, J.E.; Bhutani, V.K.; Carlo, W.A.; Cummings, J.; Kumar, P.; Tan, R.C.; Wang, K.S.; et al. Management of neonates with suspected or proven early-onset bacterial sepsis. Pediatrics 2012, 129, 1006–1015. [Google Scholar] [CrossRef] [PubMed]
  23. Boscarino, G.; Romano, R.; Iotti, C.; Tegoni, F.; Perrone, S.; Esposito, S. An overview of antibiotic therapy for early-and late-onset neonatal sepsis: Current strategies and future prospects. Antibiotics 2024, 13, 250. [Google Scholar] [CrossRef] [PubMed]
  24. Hodoșan, V.; Daina, C.M.; Zaha, D.C.; Cotrău, P.; Vladu, A.; Pantiș, C.; Dorobanțu, F.R.; Negrău, M.; Maghiar, A.; Daina, L.G. Pattern of antibiotic use in the perinatal period in a public university hospital in Romania. Medicina 2022, 58, 772. [Google Scholar] [CrossRef] [PubMed]
  25. Abushaheen, M.A.; Muzaheed; Fatani, A.J.; Alosaimi, M.; Mansy, W.; George, M.; Acharya, S.; Rathod, S.; Divakar, D.D.; Jhugroo, C.; et al. Antimicrobial resistance, mechanisms and its clinical significance. Disease-a-Month 2020, 66, 100971. [Google Scholar] [CrossRef]
  26. Rallis, D.; Giapros, V.; Serbis, A.; Kosmeri, C.; Baltogianni, M. Fighting antimicrobial resistance in neonatal intensive care units: Rational use of antibiotics in neonatal sepsis. Antibiotics 2023, 12, 508. [Google Scholar] [CrossRef] [PubMed]
  27. Ibrahim, S.; Al-Saryi, N.; Al-Kadmy, I.M.; Aziz, S.N. Multidrug-resistant Acinetobacter baumannii as an emerging concern in hospitals. Mol. Biol. Rep. 2021, 48, 6987–6998. [Google Scholar] [CrossRef]
  28. Al Bshabshe, A.; Al-Hakami, A.; Alshehri, B.; Al-Shahrani, K.A.; Alshehri, A.A.; Al Shahrani, M.B.; Assiry, I.; Joseph, M.R.; Alkahtani, A.M.; Hamid, M.E. Rising Klebsiella pneumoniae infections and its expanding drug resistance in the intensive care unit of a tertiary Healthcare Hospital, Saudi Arabia. Cureus 2020, 12, e10060. [Google Scholar] [CrossRef]
  29. Ting, J.Y.; Autmizguine, J.; Dunn, M.S.; Choudhury, J.; Blackburn, J.; Gupta-Bhatnagar, S.; Assen, K.; Emberley, J.; Khan, S.; Leung, J.; et al. Practice summary of antimicrobial therapy for commonly encountered conditions in the neonatal intensive care unit: A Canadian perspective. Front. Pediatr. 2022, 10, 894005. [Google Scholar] [CrossRef]
  30. Kasem, S.; Elhadidi, A.; Omar, N.; Dawoud, T.; Sa’da, O.A.; Rahmani, A.; Khan, N. Microbiological Characteristics and Resistance Patterns in a Neonatal Intensive Care Unit: A Retrospective Surveillance Study. Cureus 2024, 16, e56027. [Google Scholar] [CrossRef] [PubMed]
  31. Romandini, A.; Pani, A.; Schenardi, P.A.; Pattarino GA, C.; De Giacomo, C.; Scaglione, F. Antibiotic resistance in pediatric infections: Global emerging threats, predicting the near future. Antibiotics 2021, 10, 393. [Google Scholar] [CrossRef]
  32. Naylor, N.R.; Atun, R.; Zhu, N.; Kulasabanathan, K.; Silva, S.; Chatterjee, A.; Knight, G.M.; Robotham, J.V. Estimating the burden of antimicrobial resistance: A systematic literature review. Antimicrob. Resist. Infect. Control 2018, 7, 58. [Google Scholar] [CrossRef] [PubMed]
  33. Bilal, H.; Khan, M.N.; Rehman, T.; Hameed, M.F.; Yang, X. Antibiotic resistance in Pakistan: A systematic review of past decade. BMC Infect. Dis. 2021, 21, 244. [Google Scholar] [CrossRef]
  34. Jubeh, B.; Breijyeh, Z.; Karaman, R. Resistance of gram-positive bacteria to current antibacterial agents and overcoming approaches. Molecules 2020, 25, 2888. [Google Scholar] [CrossRef]
  35. Sands, K.; Spiller, O.B.; Thomson, K.; Portal, E.A.; Iregbu, K.C.; Walsh, T.R. Early-onset neonatal sepsis in low-and middle-income countries: Current challenges and future opportunities. Infect. Drug Resist. 2022, 15, 933–946. [Google Scholar] [CrossRef]
  36. Chiusaroli, L.; Liberati, C.; Caseti, M.; Rulli, L.; Barbieri, E.; Giaquinto, C.; Donà, D. Therapeutic Options and Outcomes for the Treatment of Neonates and Preterms with Gram-Negative Multidrug-Resistant Bacteria: A Systematic Review. Antibiotics 2022, 11, 1088. [Google Scholar] [CrossRef] [PubMed]
  37. Christensen, E.E. Towards Improved Sepsis Delineation: Chronic Organ Failures, Infection Biomarkers, and Leukocyte Phenotypes. Ph.D. Thesis, University of Oslo, Oslo, Norway, 2024. [Google Scholar]
  38. Kakkar, A.K.; Shafiq, N.; Singh, G.; Ray, P.; Gautam, V.; Agarwal, R.; Muralidharan, J.; Arora, P. Antimicrobial stewardship programs in resource constrained environments: Understanding and addressing the need of the systems. Front. Public Health 2020, 8, 140. [Google Scholar] [CrossRef] [PubMed]
  39. Cantón, R.; Akova, M.; Langfeld, K.; Torumkuney, D. Relevance of the consensus principles for appropriate antibiotic prescribing in 2022. J. Antimicrob. Chemother. 2022, 77 (Suppl. S1), i2–i9. [Google Scholar] [CrossRef]
  40. Dikkatwar, M.S.; Vaghasiya, J. Antibiogram and antimicrobial stewardship program: Fighting global antimicrobial resistance and rationalizing the antibiotic treatment. J. Young Pharm. 2022, 15, 41–48. [Google Scholar] [CrossRef]
  41. Ryu, H.; Azim, A.A.; Bhatt, P.J.; Uprety, P.; Mohayya, S.; Dixit, D.; Kirn, T.J.; Narayanan, N. Rapid diagnostics to enhance therapy selection for the treatment of bacterial infections. Curr. Pharmacol. Rep. 2023, 9, 198–216. [Google Scholar] [CrossRef]
  42. Martínez, M.L.; Plata-Menchaca, E.P.; Ruiz-Rodríguez, J.C.; Ferrer, R. An approach to antibiotic treatment in patients with sepsis. J. Thorac. Dis. 2020, 12, 1007. [Google Scholar] [CrossRef] [PubMed]
  43. Mdarhri, H.A.; Benmessaoud, R.; Yacoubi, H.; Seffar, L.; Assimi, H.G.; Hamam, M.; Boussettine, R.; Filali-Ansari, N.; Lahlou, F.A.; Diawara, I.; et al. Alternatives therapeutic approaches to conventional antibiotics: Advantages, limitations and potential application in medicine. Antibiotics 2022, 11, 1826. [Google Scholar] [CrossRef]
  44. Williams, P.; Qazi, S.; Agarwal, R.; Velaphi, S.; Bielicki, J.; Nambiar, S.; Giaquinto, C.; Bradley, J.; Noel, G.; Ellis, S.; et al. Antibiotics needed to treat multidrug-resistant infections in neonates. Bull. World Health Organ. 2022, 100, 797. [Google Scholar] [CrossRef] [PubMed]
Table 1. Study sample characteristics (n = 266).
Table 1. Study sample characteristics (n = 266).
Factor(Mean ± SD)
Gestational age (days)35.10 ± 2.90
Hospital stay (days)18.46 ± 23.79
Birth weight (mg)2424.20 ± 845.42
FactorCategoryn (%)
GenderMale151 (56.8)
Female115 (43.2)
Previous admissionYes8 (3.0)
No258 (97.0)
Signs of infectionBradycardia7 (2.6)
Abdominal distension19 (7.1)
Vomiting25 (9.3)
Chest retraction53 (19.9)
CRP51 (19.1)
Grunting21 (7.9)
Tachypnea35 (13.2)
Fever12 (4.5)
Poor feeding16 (6.0)
Hypoactivity6 (2.3)
Mottled skin20 (7.5)
None73 (27.4)
Diagnosis on admissionTransient tachypnea of the newborn (TTN)33 (12.4)
Respiratory distress syndrome106 (39.8)
Neonatal jaundice (NNT)32 (12.0)
Cyanosis24 (9.0)
Intrauterine growth restriction (IUGR)15 (5.6)
Vomiting11 (4.1)
Birth weight categoryVery low33 (12.4)
Low93 (40.0)
Normal140 (52.6)
Gestational age categoryVery preterm33 (12.4)
Moderate to late preterm96 (36.1)
Term137 (51.5)
Type of deliveryNormal delivery102 (38.3)
Cesarean section158 (59.4)
Unknown6 (2.3)
Onset of sepsisEarly onset92 (34.6)
Late onset174 (65.4)
Early-onset sepsis according to gestational ageVery preterm4 (1.5)
Moderate to late preterm43 (16.2)
Term45 (16.9)
Late-onset sepsis according to gestational ageVery preterm29 (10.9)
Moderate to late preterm53 (19.9)
Term92 (34.6)
Patient’s prognosisDischarged260 (97.7)
Died5 (1.88)
Transferred1 (0.38)
Table 2. Characteristics of antibiotic prescription for the treatment of neonatal sepsis.
Table 2. Characteristics of antibiotic prescription for the treatment of neonatal sepsis.
FactorCategoryn (%)
Prenatal Antibiotic UseNo262 (98.5)
Yes4 (1.5)
Intrapartum antibiotic useNo266 (100)
Number of empirical antibiotics used013 (4.9)
111 (4.1)
2184 (69.2)
326 (9.8)
429 (10.9)
51 (0.4)
62 (0.8)
Antibiotics changed after cultureYes120 (45.1)
No134 (50.4)
Number of targeted antibiotics used when changing antibiotics137 (30.8)
252 (43.3)
322 (18.3)
49 (7.5)
Antibiotics prescribed in early-onset sepsisPenicillin83 (31.2)
Dehydropeptidase inhibitor/carbapenem5 (1.9)
Glycopeptide4 (1.5)
Aminoglycosides81 (30.5)
3rd-generation cephalosporin5 (1.9)
Antibiotics prescribed in late-onset sepsisPenicillin84 (31.6)
Dehydropeptidase inhibitor/carbapenem61 (22.9)
Glycopeptide50 (18.8)
Aminoglycosides101 (38.0)
3rd-generation cephalosporin14 (5.3)
Table 3. Type of bacterial infection, Gram-positive bacteria, and Gram-negative bacteria.
Table 3. Type of bacterial infection, Gram-positive bacteria, and Gram-negative bacteria.
A. Type of bacterial infection, Gram-positive bacteria, (n = 232).
Type of BacteriaEarly-Onset Sepsis
n (%)
Late-Onset Sepsis
n (%)
n (%)
Micrococcus luteus34 (14.7)53 (22.8)87 (37.5)
Staphylococcus epidermidis24 (10.3)60 (25.9)84 (36.2)
Streptococcus viridans7 (3.0)9 (3.9)16 (6.9)
MRSA3 (1.3)11 (4.7)14 (6.0)
Diphtheroids (Corynebacterium diphtheriae)5 (2.2)1 (0.4)6 (2.6)
Enterococcus faecalis3 (1.3)1 (0.4)4 (1.7)
Bacillus cereus3 (1.3)0 (0)3 (1.3)
Staphylococcus hominis1 (0.4)2 (0.9)3 (1.3)
Staphylococcus haemolyticus1 (0.4)1 (0.4)2 (0.9)
Staphylococcus aureus0 (0)2 (0.9)2 (0.9)
Streptococcus pneumoniae1 (0.4)1 (0.4)2 (0.9)
Streptococcus agalactiae1 (0.4)0 (0)1 (0.4)
B. Type of bacterial infection, Gram-negative bacteria, (n = 34)
Type of BacteriaEarly-Onset Sepsis
n (%)
Late-Onset Sepsis
n (%)
n (%)
Klebsiella pneumoniae2 (5.8)12 (35.3)14 (41.2)
Acinetobacter baumannii1 (2.9)5 (14.7)6 (17.6)
Escherichia coli1 (2.9)4 (11.8)5 (14.7)
Enterobacter cloacae3 (8.8)0 (0)3 (8.8)
Klebsiella oxytoca1 (2.9)0 (0)1 (2.9)
Acinetobacter lwoffii1 (2.9)0 (0)1 (2.9)
Sphingomonas paucimobilis1 (2.9)0 (0)1 (2.9)
Citrobacter koseri0 (0)1 (2.9)1 (2.9)
Neisseria sicca1 (2.9)0 (0)1 (2.9)
Pseudomonas aeruginosa1 (2.9)0 (0)1 (2.9)
Table 4. The group and name of antibiotics used.
Table 4. The group and name of antibiotics used.
A. Group of antibiotics used (n = 266).
Antibiotic GroupEmpiric 1
n (%)
Empiric 2
n (%)
Empiric 3
n (%)
Empiric 4
n (%)
Empiric 5
n (%)
Empiric 6
n (%)
Penicillin164 (61.7)3 (1.1)0 (0)0 (0)0 (0)0 (0)
Penicillin–beta lactamase1 (0.4)0 (0)0 (0)2 (0.8)0 (0)0 (0)
Dehydropeptidase/Carbapenem30 (11.3)36 (13.5)22(8.3)12 (4.5)2 (0.8)2 (0.8)
Glycopeptide29 (10.9)25 (9.4)10 (3.8)7 (2.6)2 (0.8)0 (0)
Aminoglycosides20 (7.5)162 (60.9)11 (4.1)6 (2.3)0 (0)0 (0)
3rd-generation Cephalosporin3 (1.1)16 (6.0)4 (1.5)1 (0.4)0 (0)0 (0)
Nitroimidazole2 (0.8)0 (0)10 (3.8)2 (0.8)0 (0)0 (0)
Polymyxins0 (0)0 (0)0 (0)1 (0.4)0 (0)0 (0)
B. Name of antibiotics used (n = 266).
AntibioticEmpiric 1
n (%)
Empiric 2
n (%)
Empiric 3
n (%)
Empiric 4
n (%)
Empiric 5
n (%)
Empiric 6
n (%)
Ampicillin164 (61.7)3 (1.1)0 (0)0 (0)0 (0)0 (0)
Amikacin19 (7.1)32 (12.0)10 (3.8)6 (2.3)0 (0)0 (0)
Meropenem21 (7.9)32 (12.0)15 (5.6)11 (4.1)2 (0.8)2 (0.8)
Vancomycin29 (10.9)25 (9.4)10 (3.8)7 (2.6)2 (0.8)0 (0)
Metronidazole2 (0.8)0 (0)10 (3.8)2 (0.8)0 (0)0 (0)
Gentamycin1 (0.4)130 (48.9)1 (0.4)0 (0)0 (0)0 (0)
Colistimethate0 (0)0 (0)0 (0)1 (0.4)0 (0)0 (0)
Piperacillin–Tazobactam1 (0.4)0 (0)0 (0)2 (0.8)0 (0)0 (0)
Cefotaxime3 (1.1)16 (6.0)4 (1.5)1 (0.4)0 (0)0 (0)
Cilastatin/imipenem9 (3.4)0 (0)7 (2.6)1 (0.4)0 (0)0 (0)
Table 5. The group and name of antibiotics changed.
Table 5. The group and name of antibiotics changed.
A. Group of antibiotics changed (n = 120).
Antibiotic GroupChanged 1
n (%)
Changed 2
n (%)
Changed 3
n (%)
Changed 4
n (%)
Penicillin8 (6.7)2 (1.7)1 (0.8)0 (0)
Penicillin–beta lactamase1 (0.8)1 (0.8)0 (0)0 (0)
Glycopeptide41 (34.2)16 (13.3)5 (4.2)0 (0)
Dehydropeptidase/Carbapenem17 (14.2)39 (32.5)11 (9.2)4 (3.3)
Aminoglycosides34 (28.3)18 (15.0)4 (3.3)0 (0)
3rd-generation Cephalosporin11 (9.2)6 (5.0)2 (1.7)2 (1.7)
Nitroimidazole2 (1.7)1 (0.8)2 (1.7)1 (0.8)
Polymyxins4 (3.3)0 (0)1 (0.8)0 (0)
Macrolide1 (0.8)0 (0)0 (0)0 (0)
Sulfonamide/diaminopyridine1 (0.8)0 (0)3 (2.5)1 (0.8)
B. Name of antibiotics changed (n = 120).
AntibioticChanged #1
n (%)
Changed #2
n (%)
Changed #3
n (%)
Changed #4
n (%)
Ampicillin8 (6.7)2 (1.7)1 (0.8)0 (0)
Amikacin26 (21.7)9 (7.5)3 (2.5)0 (0)
Meropenem8 (6.7)34 (28.3)8 (6.7)4 (3.3)
Vancomycin41 (34.2)16 (13.3)5 (4.2)0 (0)
Metronidazole2 (1.7)1 (0.8)2 (1.7)1 (0.8)
Gentamycin8 (6.7)9 (7.5)1 (0.8)0 (0)
Colistimethate4 (3.3)0 (0)1 (0.8)0 (0)
Piperacillin–Tazobactam1 (0.8)1 (0.8)0 (0)0 (0)
Ceftriaxone2 (1.7)0 (0)1 (0.8)0 (0)
Cefotaxime9 (7.5)6 (5.0)1 (0.8)2 (1.7)
SMX/TMP1 (0.8)0 (0)3 (2.5)1 (0.8)
Azithromycin1 (0.8)0 (0)0 (0)0 (0)
Cilastatin/imipenem9 (7.5)5 (4.2)3 (2.5)0 (0)
Table 6. Resistance patterns to antibiotics.
Table 6. Resistance patterns to antibiotics.
Antibiotic
Resistance
to Pathogens
n (%)E-coliEnterobacterK. pneumoniaMicrococcusMRSAStaph. EpidermisViridans streptococciStaphylococcus hominisAcinetobacter baumanniiSphingomonasKlebsiella oxytocaStreptococcus pneumoniaeStreptococcus mitisStaphylococcus haemolyticusEnterococcusCoagulase-negative StaphylococciStaphylococcus aureus
n
Ampicillin15 (5.6)2 1 3531
Gentamicin22 (8.3)1 7 11221112 12
Penicillin41 (15.4) 11 7113 114 3
Imipenem16 (6.0) 12 31
Meropenem14 (5.3) 10 211
Ceftriaxone16 (6.0)1 1 153 1211
Cefotaxime37 (13.9)4 11 159 31 111
Ceftazidime27 (10.2)3 11 153 111 1
Cefepime25 (9.4)2 11 152 111 1
Cefoxitin35 (13.2)1 12 753 4 3
Erythromycin20 (7.5) 5 431 1 41 1
Oxacillin33 (12.4) 11 743 1 4 3
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Alameri, M.; Gharaibeh, L.; Alsous, M.; Yaghi, A.; Tanash, A.; Sa’id, S.; Sartawi, H. Antibiotic Prescription Practice and Resistance Patterns of Bacterial Isolates from a Neonatal Intensive Care Unit: A Retrospective Study from Jordan. Antibiotics 2025, 14, 105. https://doi.org/10.3390/antibiotics14010105

AMA Style

Alameri M, Gharaibeh L, Alsous M, Yaghi A, Tanash A, Sa’id S, Sartawi H. Antibiotic Prescription Practice and Resistance Patterns of Bacterial Isolates from a Neonatal Intensive Care Unit: A Retrospective Study from Jordan. Antibiotics. 2025; 14(1):105. https://doi.org/10.3390/antibiotics14010105

Chicago/Turabian Style

Alameri, Mariam, Lobna Gharaibeh, Mervat Alsous, Aseel Yaghi, Asma’a Tanash, Saqr Sa’id, and Hanan Sartawi. 2025. "Antibiotic Prescription Practice and Resistance Patterns of Bacterial Isolates from a Neonatal Intensive Care Unit: A Retrospective Study from Jordan" Antibiotics 14, no. 1: 105. https://doi.org/10.3390/antibiotics14010105

APA Style

Alameri, M., Gharaibeh, L., Alsous, M., Yaghi, A., Tanash, A., Sa’id, S., & Sartawi, H. (2025). Antibiotic Prescription Practice and Resistance Patterns of Bacterial Isolates from a Neonatal Intensive Care Unit: A Retrospective Study from Jordan. Antibiotics, 14(1), 105. https://doi.org/10.3390/antibiotics14010105

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop